Related Experiment Video
Updated: May 29, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues
M Klincová1, V Sandecká, A Mikuláiová
1Department of Internal Medicine-Hematooncology, University Hospital Brno, Czech Republic.
Abstract:
Monoclonal gammopathy of undetermined significance (MGUS) is a precancerosis comprising two different kinds of cancer: lymphoid/lymphoplasmocytoid MGUS and plasma cell MGUS that represents about 85% of all MGUS cases. This type of MGUS has low but persistent tendency to transform to malignant disease, mainly multiple myeloma (MM), with frequency of about 1% per year. Using known risk stratification models based on clinical parameters, it is possible to identify patients' groups with average rates of progression as low as 0.26% and as high as 12% per year. However, due to the lack of clear genetic and/or phenotypic markers distinguishing MGUS from MM, we are not able to predict if and when MGUS will progress to MM in individual patients. There are partially overlapping molecular pathogenic events shared by MGUS and MM. Better understanding of pathogenesis of MGUS and MM using molecular-genetic approaches will help disclose the mechanisms of myeloma genesis; it can be also useful for identification of novel molecular targets. The ultimate goal for the near future is to develop better markers for definition of high-risk MGUS patients who will be candidates for early treatment intervention.
Insights
Monoclonal gammopathy of undetermined significance (MGUS) is a precancerous condition that can progress to multiple myeloma (MM). Current risk models are insufficient for predicting individual patient progression, highlighting the need for better molecular markers.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Monoclonal gammopathy of undetermined significance (MGUS) is a precancerous condition.
- Plasma cell MGUS constitutes 85% of cases and carries a risk of transforming into multiple myeloma (MM).
- Existing clinical risk stratification models offer limited predictive accuracy for individual patient progression.
Purpose of the Study:
- To investigate the molecular pathogenesis of MGUS and MM.
- To identify potential molecular markers for predicting MGUS progression to MM.
- To aid in the development of early treatment interventions for high-risk MGUS patients.
Main Methods:
- Review of existing literature on MGUS and MM pathogenesis.
- Analysis of molecular and genetic factors implicated in the progression of MGUS to MM.
- Evaluation of current risk stratification models.
Main Results:
- MGUS shares partially overlapping molecular pathogenic events with MM.
- Current clinical parameters lack the precision to predict individual MGUS progression.
- There is a critical need for novel genetic and phenotypic markers.
Conclusions:
- Understanding the molecular basis of MGUS and MM is crucial for identifying novel therapeutic targets.
- Development of advanced molecular markers is essential for identifying high-risk MGUS patients.
- Early identification of high-risk patients could enable timely therapeutic interventions.
